Daniel R. A. Cox, Nicholas Low, Su Kah Goh, Eunice Lee, Angela Vago, Louise Jackett, Julie Lokan, Sabine Braat, Robert Jones, Adam Testro, Alexander Dobrovic, Vijayaragavan Muralidharan – 15 December 2021 – Graft‐derived cell‐free DNA (gdcfDNA) quantification is a promising, minimally invasive tool for detecting acute T cell–mediated rejection (ATCMR) following liver transplantation (LT). We investigated the utility of measuring hepatocyte‐specific methylation in cfDNA (HS‐cfDNA) to quantify gdcfDNA, examining its accuracy in detecting ATCMR in a prospective, cross‐sectional study.

Chun‐Yan Wang, Ya Deng, Ping Li, Sujun Zheng, Guofeng Chen, Guangde Zhou, Jing Xu, Yan‐Ping Chen, Zheng Wang, Xueyuan Jin, Jin‐Mo Tang, Kun‐Peng Hu, Jing‐Feng Bi, Ping Zhang, Chun‐Xia Li, Ang Huang, Gui‐Ji Lv, Xiao‐He Xiao, Zhengsheng Zou, Dong Ji – 15 December 2021

Manhal Izzy, Lisa B. VanWagner – 15 December 2021

Atousa Khalatbari, Zahra Aghazadeh, Cheng Ji – 14 December 2021 – During the pandemic, dexamethasone (DEX), remdesivir (RDV), hydroxychloroquine (HCQ), thapsigargin (TG), camostat mesylate (CaM), and pralatrexate were repurposed drugs for coronavirus disease 2019 (COVID‐19). However, the side effects on the liver associated with the anti‐COVID therapies are unknown. Cellular stresses by these drugs at 0‐30 μM were studied using HepG2, Huh7, and/or primary human hepatocytes.

Thomas Reiberger – 13 December 2021 – Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagnosing CSPH, respectively; however, both are invasive, limiting their use in clinical practice and larger trials of novel agents.

Yuji Suzuki, Keisuke Kakisaka, Yasuhiro Takikawa – 12 December 2021

Leidy D. Caraballo Galva, Xiaotao Jiang, Mohamed S. Hussein, Huajun Zhang, Rui Mao, Pierce Brody, Yibing Peng, Aiwu Ruth He, Mercy Kehinde‐Ige, Ramses Sadek, Xiangguo Qiu, Huidong Shi, Yukai He – 11 December 2021

Lei Wei, Alexander Ploss – 9 December 2021

Hannah S.J. Choi, Alexander Tonthat, Harry L.A. Janssen, Norah A. Terrault – 9 December 2021 – Chronic hepatitis B virus (HBV) infection remains difficult to cure due to the persistent, self‐replenishing nature of the viral genome and impaired host immune responses. Current treatment goals for chronic hepatitis B (CHB) are to prevent or significantly delay liver‐related adverse outcomes and death, and two types of treatments are available: nucleos(t)ide analogues (NAs) and interferons (IFNs).

Ankur Jindal – 9 December 2021